-
Something wrong with this record ?
Hepatocyte and immune cell crosstalk in non-alcoholic fatty liver disease
AM. Carranza-Trejo, V. Vetvicka, L. Vistejnova, M. Kralickova, EB. Montufar
Language English Country Great Britain
Document type Journal Article, Review
- MeSH
- Adaptive Immunity immunology MeSH
- Hepatocytes immunology physiology MeSH
- Receptor Cross-Talk immunology physiology MeSH
- Kupffer Cells immunology MeSH
- Humans MeSH
- Lymphocytes immunology MeSH
- Non-alcoholic Fatty Liver Disease immunology physiopathology MeSH
- Oxidative Stress immunology MeSH
- Immunity, Innate immunology MeSH
- Disease Progression MeSH
- Regulated Cell Death immunology physiology MeSH
- Inflammation immunology physiopathology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
Introduction: Nonalcoholic fatty liver disease (NAFLD) is the most widespread chronic liver disease in the world. It can evolve into nonalcoholic steatohepatitis (NASH) where inflammation and hepatocyte ballooning are key participants in the determination of this steatotic state.Areas covered: To provide a systematic overview and current understanding of the role of inflammation in NAFLD and its progression to NASH, the function of the cells involved, and the activation pathways of the innate immunity and cell death; resulting in inflammation and chronic liver disease. A PubMed search was made with relevant articles together with relevant references were included for the writing of this review.Expert opinion: Innate and adaptive immunity are the key players in the NAFLD progression; some of the markers presented during NAFLD are also known to be immunity biomarkers. All cells involved in NAFLD and NASH are known to have immunoregulatory properties and their imbalance will completely change the cytokine profile and form a pro-inflammatory microenvironment. It is necessary to fully answer the question of what initiators and metabolic imbalances are particularly important, considering sterile inflammation as the architect of the disease. Due to the shortage of elucidation of NASH progression, we discuss in this review, how inflammation is a key part of this development and we presume the targets should lead to inflammation and oxidative stress treatment.
Biomedical Centre Medical Faculty in Pilsen Charles University Pilsen Czech Republic
Central European Institute of Technology Brno University of Technology Brno Czech Republic
Department of Pathology and Laboratory Medicine University of Louisville Louisville KY USA
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22004134
- 003
- CZ-PrNML
- 005
- 20220127145502.0
- 007
- ta
- 008
- 220113s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/17474124.2021.1887730 $2 doi
- 035 __
- $a (PubMed)33557653
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Carranza-Trejo, Azalia Mariel $u Biomedical Centre, Medical Faculty in Pilsen, Charles University, Pilsen, Czech Republic
- 245 10
- $a Hepatocyte and immune cell crosstalk in non-alcoholic fatty liver disease / $c AM. Carranza-Trejo, V. Vetvicka, L. Vistejnova, M. Kralickova, EB. Montufar
- 520 9_
- $a Introduction: Nonalcoholic fatty liver disease (NAFLD) is the most widespread chronic liver disease in the world. It can evolve into nonalcoholic steatohepatitis (NASH) where inflammation and hepatocyte ballooning are key participants in the determination of this steatotic state.Areas covered: To provide a systematic overview and current understanding of the role of inflammation in NAFLD and its progression to NASH, the function of the cells involved, and the activation pathways of the innate immunity and cell death; resulting in inflammation and chronic liver disease. A PubMed search was made with relevant articles together with relevant references were included for the writing of this review.Expert opinion: Innate and adaptive immunity are the key players in the NAFLD progression; some of the markers presented during NAFLD are also known to be immunity biomarkers. All cells involved in NAFLD and NASH are known to have immunoregulatory properties and their imbalance will completely change the cytokine profile and form a pro-inflammatory microenvironment. It is necessary to fully answer the question of what initiators and metabolic imbalances are particularly important, considering sterile inflammation as the architect of the disease. Due to the shortage of elucidation of NASH progression, we discuss in this review, how inflammation is a key part of this development and we presume the targets should lead to inflammation and oxidative stress treatment.
- 650 _2
- $a adaptivní imunita $x imunologie $7 D056704
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a hepatocyty $x imunologie $x fyziologie $7 D022781
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a přirozená imunita $x imunologie $7 D007113
- 650 _2
- $a zánět $x imunologie $x patofyziologie $7 D007249
- 650 _2
- $a Kupfferovy buňky $x imunologie $7 D007728
- 650 _2
- $a lymfocyty $x imunologie $7 D008214
- 650 _2
- $a nealkoholová steatóza jater $x imunologie $x patofyziologie $7 D065626
- 650 _2
- $a oxidační stres $x imunologie $7 D018384
- 650 _2
- $a interakce mezi receptory a ligandy $x imunologie $x fyziologie $7 D020239
- 650 _2
- $a regulovaná buněčná smrt $x imunologie $x fyziologie $7 D000079404
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Vetvicka, Vaclav $u Department of Pathology and Laboratory Medicine, University of Louisville, Louisville, KY, USA
- 700 1_
- $a Vistejnova, Lucie $u Biomedical Centre, Medical Faculty in Pilsen, Charles University, Pilsen, Czech Republic
- 700 1_
- $a Kralickova, Milena $u Biomedical Centre, Medical Faculty in Pilsen, Charles University, Pilsen, Czech Republic
- 700 1_
- $a Montufar, Edgar B $u Central European Institute of Technology, Brno University of Technology, Brno, Czech Republic
- 773 0_
- $w MED00174418 $t Expert review of gastroenterology & hepatology $x 1747-4132 $g Roč. 15, č. 7 (2021), s. 783-796
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33557653 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20220127145458 $b ABA008
- 999 __
- $a ok $b bmc $g 1751564 $s 1155283
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 15 $c 7 $d 783-796 $e 20210218 $i 1747-4132 $m Expert review of gastroenterology & hepatology $n Expert Rev Gastroenterol Hepatol $x MED00174418
- LZP __
- $a Pubmed-20220113